75% of Merkel Cell Tumors Contain Virus-Specific Immune Cells That Could Power Vaccines
9 of 12 Merkel cell carcinoma patients had virus-specific CD8+ T cells within their tumors, recognizing 1–8 viral epitopes with potential 97% population coverage.
Quick Facts
What This Study Found
Tumor-infiltrating lymphocytes from 9 of 12 patients (75%) contained CD8+ T cells that recognized Merkel cell polyomavirus T-antigen. Each patient's immune cells recognized between 1 and 8 different viral epitopes.
Analysis of 16 identified epitopes showed that 97% of patients with virus-positive Merkel cell carcinoma had the HLA alleles needed to mount CD8+ T cell responses against the viral proteins.
The amino acid region 70-110 of the large T antigen was especially rich in immune targets, while the oncogenic domains were not commonly recognized. This is important because a vaccine could focus on the immunogenic region while avoiding the cancer-causing parts.
Key Numbers
9/12 (75%) had virus-specific TILs; 1-8 epitopes per patient; 16 epitopes mapped; 97% HLA coverage
How They Did This
Researchers extracted tumor-infiltrating lymphocytes from 12 Merkel cell carcinoma patients. They used artificial antigen-presenting cells, synthetic peptides, HLA-peptide tetramers, and dendritic cells to identify which viral epitopes the immune cells recognized. They also analyzed HLA allele coverage across patients.
Why This Research Matters
About half of Merkel cell carcinoma patients respond to immune checkpoint inhibitors. Finding that most tumors already contain virus-specific immune cells suggests the raw ingredients for an immune response are present. A vaccine could boost these existing immune cells.
The fact that immunogenic regions are separate from oncogenic regions means a vaccine could be designed that is both effective and safe, without risk of promoting cancer growth.
The Bigger Picture
About half of MCC patients respond to immune checkpoint inhibitors. Finding that most tumors already contain virus-specific immune cells suggests combining checkpoint therapy with a viral peptide vaccine could boost response rates, particularly in non-responders.
What This Study Doesn't Tell Us
This was a small study with only 12 patients. While the HLA coverage analysis extended to a broader population, the direct T cell findings came from a limited sample.
The study did not test whether boosting these T cell responses with a vaccine would actually shrink tumors.
Questions This Raises
- ?Would a peptide vaccine targeting these epitopes improve checkpoint inhibitor response rates?
- ?Why do 25% of patients lack detectable virus-specific TILs?
- ?Can vaccine design safely include viral antigens without oncogenic domains?
Trust & Context
- Key Stat:
- 97% coverage 16 identified viral epitopes collectively cover 97% of virus-positive Merkel cell carcinoma patients by HLA type
- Evidence Grade:
- Moderate evidence from direct analysis of human tumor-infiltrating lymphocytes. Small patient sample (n=12) but high-quality immunological characterization.
- Study Age:
- Published in 2020. Therapeutic vaccines for virus-driven cancers continue advancing in clinical trials.
- Original Title:
- Prevalent and Diverse Intratumoral Oncoprotein-Specific CD8+ T Cells within Polyomavirus-Driven Merkel Cell Carcinomas.
- Published In:
- Cancer immunology research, 8(5), 648-659 (2020)
- Authors:
- Jing, Lichen, Ott, Mariliis, Church, Candice D, Kulikauskas, Rima M, Ibrani, Dafina, Iyer, Jayasri G, Afanasiev, Olga K, Colunga, Aric, Cook, Maclean M, Xie, Hong, Greninger, Alexander L, Paulson, Kelly G, Chapuis, Aude G, Bhatia, Shailender, Nghiem, Paul, Koelle, David M
- Database ID:
- RPEP-04888
Evidence Hierarchy
Frequently Asked Questions
Why do some cancer tumors contain immune cells?
The immune system recognizes viral proteins in MCC tumors as foreign. T cells infiltrate the tumor to attack it, but the tumor often suppresses them. Checkpoint inhibitors remove the suppression; a vaccine could boost the attacking T cells.
Could a Merkel cell carcinoma vaccine work?
The finding that most tumors already contain the right immune cells, and that 16 peptides cover 97% of patients, provides strong rationale for developing a therapeutic vaccine to boost these existing anti-tumor responses.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-04888APA
Jing, Lichen; Ott, Mariliis; Church, Candice D; Kulikauskas, Rima M; Ibrani, Dafina; Iyer, Jayasri G; Afanasiev, Olga K; Colunga, Aric; Cook, Maclean M; Xie, Hong; Greninger, Alexander L; Paulson, Kelly G; Chapuis, Aude G; Bhatia, Shailender; Nghiem, Paul; Koelle, David M. (2020). Prevalent and Diverse Intratumoral Oncoprotein-Specific CD8+ T Cells within Polyomavirus-Driven Merkel Cell Carcinomas.. Cancer immunology research, 8(5), 648-659. https://doi.org/10.1158/2326-6066.CIR-19-0647
MLA
Jing, Lichen, et al. "Prevalent and Diverse Intratumoral Oncoprotein-Specific CD8+ T Cells within Polyomavirus-Driven Merkel Cell Carcinomas.." Cancer immunology research, 2020. https://doi.org/10.1158/2326-6066.CIR-19-0647
RethinkPeptides
RethinkPeptides Research Database. "Prevalent and Diverse Intratumoral Oncoprotein-Specific CD8+..." RPEP-04888. Retrieved from https://rethinkpeptides.com/research/jing-2020-prevalent-and-diverse-intratumoral
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.